ArticleCardiovascular drugs and therapy2019

Characteristics and Cardiovascular Disease Event Rates among African Americans and Whites Who Meet the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) Trial Inclusion Criteria.

Lisandro D Colantonio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.